Active	Status	Sponsor type	Region	Phase	Filter
26 Active 1 Inactive 27 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

26 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Patel, Kalpesh R
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent	Terminated	3	105	US	VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga	Veru Inc.	Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer	05/23	05/23
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)	Recruiting	3	10000	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)	02/29	02/29
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	Active, not recruiting	3	15374	Europe, Canada, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Overweight	10/27	10/27
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
VERU-100, NCT04843319: To Determine an Effective Dose of for the Treatment of Advanced Prostate Cancer	Terminated	1b/2	24	US	VERU-100	Veru Inc.	Advanced Prostate Adenocarcinoma	01/23	01/23
NCT04770441: Transoral Incisionless Fundoplication in Post-POEM GERD	Completed	N/A	7	US		Baylor College of Medicine	Swallowing Disorders, Achalasia, Outlet Obstruction, Gastric, Diffuse Esophageal Spasm	10/22	06/23
AEROLITH, NCT04563039: Acoustic Enhancer Research on Laser Lithotripsy	Completed	N/A	196	US	Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer, Standard Ureteroscopic Laser Lithotripsy	Avvio Medical	Urinary Stones	07/23	07/23
STEP-1, NCT04101669: RESET System Pivotal Trial (Rev F)	Recruiting	N/A	264	US	RESET Liner, RESET Sleeve, Duodenal-jejunal Bypass Liner (DJBL), EndoBarrier, Sham	Morphic Medical Inc., Biostatistical Consulting, Inc.	Diabetes type2, Obesity	12/25	12/26
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift	Recruiting	N/A	206	Europe, US	iTind, UroLift	Olympus Corporation of the Americas	Benign Prostatic Hyperplasia (BPH)	12/25	12/30
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer	Active, not recruiting	N/A	400	US	Vanquish System	Francis Medical Inc.	Prostate Cancer	04/27	04/29
Belkoff, Kenneth
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin	Recruiting	3	190	Japan, US, RoW	Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer	12/27	12/29
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
O'Brien, Katie
STREAM, NCT05383274: Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters	Recruiting	4	34	US	Optilume Urethral DCB	Urotronic Inc., Laborie Medical Technologies Inc.	Urethral Stricture	12/25	12/26
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
NMIBC, NCT05483868: A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer	Recruiting	1	21	US	AU-011, AU-011 in Combination with Medical Laser Adminstration, AU-011 in Combination with Medical Laser Administration	Aura Biosciences	Non-muscle-invasive Bladder Cancer, Muscle-Invasive Bladder Carcinoma	06/24	07/24
NCT05375903: A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)	Active, not recruiting	1	51	Europe, US	UGN-301, UGN-301 (zalifrelimab) intravesical solution, UGN-201, UGN-201 (imiquimod) intravesical solution, Gemcitabine	UroGen Pharma Ltd.	Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent	12/25	12/25
AEROLITH, NCT04563039: Acoustic Enhancer Research on Laser Lithotripsy	Completed	N/A	196	US	Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer, Standard Ureteroscopic Laser Lithotripsy	Avvio Medical	Urinary Stones	07/23	07/23
NCT06090331: 89Zr-DFO-girentuximab Expanded Access Program (EAP)	Available	N/A		US	89Zr-DFO-girentuximab	Telix Pharmaceuticals (Innovations) Pty Limited	Clear Cell Renal Cell Carcinoma
NCT05643690: Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay	Suspended	N/A	77	US	UriFind Bladder Cancer Assay	AnchorDx Medical Co. Ltd. US, AnchorDx Medical Co., Ltd., Specialty Networks	Bladder Cancer	12/25	12/25
PEAK, NCT06312722: Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study	Recruiting	N/A	92	US	Optilume® BPH Catheter System	Urotronic Inc.	Benign Prostatic Hyperplasia	02/31	02/31
Henderson, R Jonathan
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
NCT05375903: A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)	Active, not recruiting	1	51	Europe, US	UGN-301, UGN-301 (zalifrelimab) intravesical solution, UGN-201, UGN-201 (imiquimod) intravesical solution, Gemcitabine	UroGen Pharma Ltd.	Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent	12/25	12/25
Navarrette, Andrea
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
VERU-100, NCT04843319: To Determine an Effective Dose of for the Treatment of Advanced Prostate Cancer	Terminated	1b/2	24	US	VERU-100	Veru Inc.	Advanced Prostate Adenocarcinoma	01/23	01/23
AEROLITH, NCT04563039: Acoustic Enhancer Research on Laser Lithotripsy	Completed	N/A	196	US	Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer, Standard Ureteroscopic Laser Lithotripsy	Avvio Medical	Urinary Stones	07/23	07/23
NCT04519294: Comparison of Laser Lithotripsy With and Without Steerable Ureteroscopic Renal Evacuation (SURE)	Active, not recruiting	N/A	162	US	SURE, Standard Ureteroscopy (Basketing)	Calyxo, Inc.	Kidney Stone, Renal Stone, Urolithiasis	04/25	04/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Patel, Kalpesh R
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent	Terminated	3	105	US	VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga	Veru Inc.	Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer	05/23	05/23
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)	Recruiting	3	10000	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)	02/29	02/29
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	Active, not recruiting	3	15374	Europe, Canada, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Overweight	10/27	10/27
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
VERU-100, NCT04843319: To Determine an Effective Dose of for the Treatment of Advanced Prostate Cancer	Terminated	1b/2	24	US	VERU-100	Veru Inc.	Advanced Prostate Adenocarcinoma	01/23	01/23
NCT04770441: Transoral Incisionless Fundoplication in Post-POEM GERD	Completed	N/A	7	US		Baylor College of Medicine	Swallowing Disorders, Achalasia, Outlet Obstruction, Gastric, Diffuse Esophageal Spasm	10/22	06/23
AEROLITH, NCT04563039: Acoustic Enhancer Research on Laser Lithotripsy	Completed	N/A	196	US	Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer, Standard Ureteroscopic Laser Lithotripsy	Avvio Medical	Urinary Stones	07/23	07/23
STEP-1, NCT04101669: RESET System Pivotal Trial (Rev F)	Recruiting	N/A	264	US	RESET Liner, RESET Sleeve, Duodenal-jejunal Bypass Liner (DJBL), EndoBarrier, Sham	Morphic Medical Inc., Biostatistical Consulting, Inc.	Diabetes type2, Obesity	12/25	12/26
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift	Recruiting	N/A	206	Europe, US	iTind, UroLift	Olympus Corporation of the Americas	Benign Prostatic Hyperplasia (BPH)	12/25	12/30
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer	Active, not recruiting	N/A	400	US	Vanquish System	Francis Medical Inc.	Prostate Cancer	04/27	04/29
Belkoff, Kenneth
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin	Recruiting	3	190	Japan, US, RoW	Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer	12/27	12/29
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
O'Brien, Katie
STREAM, NCT05383274: Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters	Recruiting	4	34	US	Optilume Urethral DCB	Urotronic Inc., Laborie Medical Technologies Inc.	Urethral Stricture	12/25	12/26
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
NMIBC, NCT05483868: A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer	Recruiting	1	21	US	AU-011, AU-011 in Combination with Medical Laser Adminstration, AU-011 in Combination with Medical Laser Administration	Aura Biosciences	Non-muscle-invasive Bladder Cancer, Muscle-Invasive Bladder Carcinoma	06/24	07/24
NCT05375903: A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)	Active, not recruiting	1	51	Europe, US	UGN-301, UGN-301 (zalifrelimab) intravesical solution, UGN-201, UGN-201 (imiquimod) intravesical solution, Gemcitabine	UroGen Pharma Ltd.	Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent	12/25	12/25
AEROLITH, NCT04563039: Acoustic Enhancer Research on Laser Lithotripsy	Completed	N/A	196	US	Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer, Standard Ureteroscopic Laser Lithotripsy	Avvio Medical	Urinary Stones	07/23	07/23
NCT06090331: 89Zr-DFO-girentuximab Expanded Access Program (EAP)	Available	N/A		US	89Zr-DFO-girentuximab	Telix Pharmaceuticals (Innovations) Pty Limited	Clear Cell Renal Cell Carcinoma
NCT05643690: Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay	Suspended	N/A	77	US	UriFind Bladder Cancer Assay	AnchorDx Medical Co. Ltd. US, AnchorDx Medical Co., Ltd., Specialty Networks	Bladder Cancer	12/25	12/25
PEAK, NCT06312722: Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study	Recruiting	N/A	92	US	Optilume® BPH Catheter System	Urotronic Inc.	Benign Prostatic Hyperplasia	02/31	02/31
Henderson, R Jonathan
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
NCT05375903: A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)	Active, not recruiting	1	51	Europe, US	UGN-301, UGN-301 (zalifrelimab) intravesical solution, UGN-201, UGN-201 (imiquimod) intravesical solution, Gemcitabine	UroGen Pharma Ltd.	Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent	12/25	12/25
Navarrette, Andrea
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
VERU-100, NCT04843319: To Determine an Effective Dose of for the Treatment of Advanced Prostate Cancer	Terminated	1b/2	24	US	VERU-100	Veru Inc.	Advanced Prostate Adenocarcinoma	01/23	01/23
AEROLITH, NCT04563039: Acoustic Enhancer Research on Laser Lithotripsy	Completed	N/A	196	US	Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer, Standard Ureteroscopic Laser Lithotripsy	Avvio Medical	Urinary Stones	07/23	07/23
NCT04519294: Comparison of Laser Lithotripsy With and Without Steerable Ureteroscopic Renal Evacuation (SURE)	Active, not recruiting	N/A	162	US	SURE, Standard Ureteroscopy (Basketing)	Calyxo, Inc.	Kidney Stone, Renal Stone, Urolithiasis	04/25	04/25